The objective of this guideline is to provide healthcare professionals with clear guidance on the management of patients with relapsed and refractory multiple myeloma who have disease progression after at least one prior therapy. These guidelines and recommendations do not replace multidisciplinary discussion and the need to take account of clinical features, patient preference and the funding and reimbursement of treatments at any given point in time.
Declaration of Interests
The BSH paid the expenses incurred during the writing of this good practice paper. All authors have made a declaration of interests to the BSH and Task Force Chairs which may be viewed on request.